North America Pharmacogenetic Testing In Psychiatry Depression Market Analysis

Customize Your Report Customize Your Report Buy Now Buy Now Free Sample Report Free Sample Report
Home Medical Devices North America Pharmacogenetic Testing In Psychiatry Depression Market Market Analysis
Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

North America Pharmacogenetic Testing In Psychiatry Depression Market Analysis

  • Medical Devices
  • Published Report
  • Sep 2022
  • North America
  • 350 Pages
  • No of Tables: 140
  • No of Figures: 48
Buy Now Buy Now

Table of Content

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of North America pharmacogenetic testing in psychiatry/depression market
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. type LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. market application coverage grid
    11. vendor share analysis
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insights
  5. REGULATIONS: North America pharmacogenetic testing IN PSYCHIATRY/DEPRESSION MARKET
    1. UNITED STATES
      1. ROLE OF FDA
      2. ROLE OF CDC AND HCFA
  6. market overview
    1. drivers
      1. RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
      2. INITIATIVES TAKEN BY MANUFACTURERS
      3. GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
      4. INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
    2. RESTRAINTS
      1. LACK OF STRONG CLINICAL EVIDENCE
      2. HIGH COST
      3. LACK OF REIMBURSEMENT
    3. OPPORTUNITIES
      1. TECHNOLOGICAL ADVANCEMENTS
      2. EMERGENCE OF NEW PLAYERS
      3. Untapped market
    4. CHALLENGES
      1. STRINGENT GOVERNMENT REGULATION
      2. SHORTAGE OF SKILLED PERSONNEL
  7. COVID-19 IMPACT ON North America pharmacogenetic testing IN PSYCHIATRY/DEPRESSION MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY
    4. KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
    5. CONCLUSION:
  8. NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE
    1. overview
    2. WHOLE GENOME SEQUENCING
    3. array-based TESTS
  9. NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES
    1. overview
    2. cyp2c19
    3. CYP2C9 and VKORC1
    4. cyp2d6
    5. HLA-B
    6. htr2a/c
    7. HLA-A
    8. cyp3A4
    9. slc6a4
    10. MTHFR
    11. COMT
    12. others
  10. NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE
    1. overview
    2. PRESCRIPTION DRUGS
    3. Over-the-counter medications
    4. RECREATIONAL DRUGS
    5. VITAMINS/NUTRACEUTICals
  11. NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE
    1. overview
    2. SALIVA
    3. BLOOD
  12. NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY application
    1. overview
    2. DRUG DEVELOPMENT
    3. CLINICAL PRACTICE
  13. NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER
    1. overview
    2. pharmaceutical and biotechnology companies
    3. HEALTHCARE PROVIDERS
    4. research centers and academic institutes
    5. others
  14. NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL
    1. overview
    2. RETAIL PHARMACIES
    3. HOSPITAL PHARMACIES
    4. MAIL-ORDER PHARMACIES
    5. DIRECt-to-customer services
  15. NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, by Country
    1. u.s.
    2. canada
    3. mexico
  16. North America pharmacogenetic testing in psychiatry/depression market: COMPANY landscape
    1. company share analysis: North America
  17. swot analysis
  18. company profile
    1. MYRIAD GENETICS, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    2. THERMO FISHER SCIENTIFIC INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    3. sonic healthcare
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    4. Illumina, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. AB-Biotics, S.A.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. 6.3 PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    6. ALTHEADX
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    7. biogeniq inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    8. Color
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    9. cnsdose
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    10. CORIELL LIFE SCIENCES
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    11. Dynamic DNA Laboratories
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    12. GENELEX
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    13. genomind, inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    14. genxys
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    15. HEALTHSPEK
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    16. HudsonAlpha Health Alliance (A Division of HudsonAlpha)
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    17. luminex corporation
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    18. MILLENNIUM HEALTH
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    19. mydna life australia pty ltd.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    20. oneome
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    21. OMECARE
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    22. PerkinElmer Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    23. R-Biopharm AG
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  19. questionnaire
  20. related reports

List of Table

TABLE 1 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2019-2028 (USD Million)

TABLE 2 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2019-2028 (USD Million)

TABLE 3 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2019-2028 (USD Million)

TABLE 4 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2019-2028 (USD Million)

TABLE 5 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2019-2028 (USD Million)

TABLE 6 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2019-2028 (USD Million)

TABLE 7 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD Million)

TABLE 8 North America pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2019-2028 (USD MILLION)

TABLE 9 u.s. pharmacogenetic testing in psychiatry/depression Market, By type, 2019-2028 (USD MILLION)

TABLE 10 u.s. pharmacogenetic testing in psychiatry/depression Market, By genes, 2019-2028 (USD MILLION)

TABLE 11 u.s. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2019-2028 (USD MILLION)

TABLE 12 u.s. pharmacogenetic testing in psychiatry/depression Market, By sample, 2019-2028 (USD MILLION)

TABLE 13 u.s. pharmacogenetic testing in psychiatry/depression Market, By application, 2019-2028 (USD MILLION)

TABLE 14 u.s. pharmacogenetic testing in psychiatry/depression Market, By end user, 2019-2028 (USD MILLION)

TABLE 15 u.s. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2019-2028 (USD MILLION)

TABLE 16 canada pharmacogenetic testing in psychiatry/depression Market, By type, 2019-2028 (USD MILLION)

TABLE 17 canada pharmacogenetic testing in psychiatry/depression Market, By genes, 2019-2028 (USD MILLION)

TABLE 18 canada pharmacogenetic testing in psychiatry/depression Market, By drug type, 2019-2028 (USD MILLION)

TABLE 19 canada pharmacogenetic testing in psychiatry/depression Market, By sample, 2019-2028 (USD MILLION)

TABLE 20 canada pharmacogenetic testing in psychiatry/depression Market, By application, 2019-2028 (USD MILLION)

TABLE 21 canada pharmacogenetic testing in psychiatry/depression Market, By end user, 2019-2028 (USD MILLION)

TABLE 22 canada pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2019-2028 (USD MILLION)

TABLE 23 mexico pharmacogenetic testing in psychiatry/depression Market, By type, 2019-2028 (USD MILLION)

TABLE 24 mexico pharmacogenetic testing in psychiatry/depression Market, By genes, 2019-2028 (USD MILLION)

TABLE 25 mexico pharmacogenetic testing in psychiatry/depression Market, By drug type, 2019-2028 (USD MILLION)

TABLE 26 mexico pharmacogenetic testing in psychiatry/depression Market, By sample, 2019-2028 (USD MILLION)

TABLE 27 mexico pharmacogenetic testing in psychiatry/depression Market, By application, 2019-2028 (USD MILLION)

TABLE 28 mexico pharmacogenetic testing in psychiatry/depression Market, By end user, 2019-2028 (USD MILLION)

TABLE 29 mexico pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 North America PHARMACOGENETIC TESTIG IN PSYCHIATRY/DEPRESSION market: segmentation

FIGURE 2 North America pharmacogenetic testing IN PSYCHIATRIC/DEPRESSION market: data triangulation

FIGURE 3 North America pharmacogenetic testing IN PSYCHIATRIC/DEPRESSION market: DROC ANALYSIS

FIGURE 4 North America pharmacogenetic testing IN PSYCHIATRIC/DEPRESSION market: Region vs country MARKET ANALYSIS

FIGURE 5 North America pharmacogenetic testing IN PSYCHIATRIC/DEPRESSION market: COMPANY RESEARCH ANALYSIS

FIGURE 6 North America pharmacogenetic testing IN PSYCHIATRIC/DEPRESSION market: DBMR MARKET POSITION GRID

FIGURE 7 North America pharmacogenetic testing in psychiatry/depression market: MARKET APPLICATION COVERAGE GRID

FIGURE 8 North America pharmacogenetic testing in psychiatry/depression market: vendor share analysis

FIGURE 9 North America pharmacogenetic testing in psychiatry/depression market: SEGMENTATION

FIGURE 10 initiatives taken by manufacturers is expected to drive THE North America pharmacogenetic testing in psychiatry/depression market IN THE FORECAST PERIOD of 2021 to 2028

FIGURE 11 whole genome sequencing segment is expected to account for the largest share of the North America pharmacogenetic testing in psychiatry/depression market in 2021 & 2028

FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF North America pharmacogenetic testing IN PSYCHIATRY/DEPRESSION MARKET

FIGURE 13 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028

FIGURE 14 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2019-2028 (USD MILLION)

FIGURE 15 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 16 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 17 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2019-2028 (USD MILLION)

FIGURE 18 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2019-2028 (USD MILLION)

FIGURE 19 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR 2019-2028 (USD MILLION)

FIGURE 20 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE

FIGURE 21 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028

FIGURE 22 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)

FIGURE 23 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR 2019-2028 (USD MILLION)

FIGURE 24 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 25 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2019-2028 (USD MILLION)

FIGURE 26 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2019-2028 (USD MILLION)

FIGURE 27 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)

FIGURE 28 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 29 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2019-2028 (USD MILLION)

FIGURE 30 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2019-2028 (USD MILLION)

FIGURE 31 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR 2019-2028 (USD MILLION)

FIGURE 32 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 33 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2019-2028 (USD MILLION)

FIGURE 34 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2019-2028 (USD MILLION)

FIGURE 35 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR 2019-2028 (USD MILLION)

FIGURE 36 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

FIGURE 38 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

FIGURE 39 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR 2019-2028 (USD MILLION)

FIGURE 40 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 North America PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 42 North America PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 43 North America PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 44 North America PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 45 North America PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 46 North America pharmacogenetic TESTING IN psychiatry/depression market: company share 2020 (%)

Browse Related Pages

Banner